BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moller S, Henriksen JH, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int. 2008;2:416-428. [PMID: 19669317 DOI: 10.1007/s12072-008-9100-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Wanninger J, Weigert J, Wiest R, Bauer S, Karrasch T, Farkas S, Scherer MN, Walter R, Weiss TS, Hellerbrand C. Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. Cytokine. 2011;55:435-440. [PMID: 21715185 DOI: 10.1016/j.cyto.2011.06.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
2 Bauer S, Eisinger K, Wiest R, Karrasch T, Scherer MN, Farkas S, Aslanidis C, Buechler C. Connective tissue growth factor level is increased in patients with liver cirrhosis but is not associated with complications or extent of liver injury. Regulatory Peptides 2012;179:10-4. [DOI: 10.1016/j.regpep.2012.08.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
3 Durdu MS, Cakici M, Gumus F, Deniz GC, Bozdag SC, Ozcinar E, Yaman ND, Ilhan O, Ucanok K. Promising utilization areas of therapeutic plasmapheresis in cardiovascular surgery practice. Transfus Apher Sci 2018;57:762-7. [PMID: 30249533 DOI: 10.1016/j.transci.2018.09.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Walayat S, Martin D, Patel J, Ahmed U, N Asghar M, Pai AU, Dhillon S. Role of albumin in cirrhosis: from a hospitalist's perspective. J Community Hosp Intern Med Perspect. 2017;7:8-14. [PMID: 28634518 DOI: 10.1080/20009666.2017.1302704] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
5 Risør LM, Fenger M, Olsen NV, Møller S. Hepatic erythropoietin response in cirrhosis. A contemporary review. Scand J Clin Lab Invest 2016;76:183-9. [PMID: 26919118 DOI: 10.3109/00365513.2016.1143563] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Matyas C, Haskó G, Liaudet L, Trojnar E, Pacher P. Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications. Nat Rev Cardiol 2021;18:117-35. [PMID: 32999450 DOI: 10.1038/s41569-020-0433-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
7 Møller S, Krag A, Bendtsen F. Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. Liver Int 2014;34:1153-63. [DOI: 10.1111/liv.12549] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
8 Aller MA, Prieto I, Argudo S, de Vicente F, Santamaría L, de Miguel MP, Arias JL, Arias J. The interstitial lymphatic peritoneal mesothelium axis in portal hypertensive ascites: when in danger, go back to the sea. Int J Inflam. 2010;2010:148689. [PMID: 21152120 DOI: 10.4061/2010/148689] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
9 Huang Y, Sun J, Wang J, Bai C, He B. Terlipressin Resolves Ascites of Cirrhotic Rats through Downregulation of Aquaporin 2. J Int Med Res 2012;40:1735-44. [DOI: 10.1177/030006051204000512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
10 Eisinger K, Krautbauer S, Wiest R, Karrasch T, Hader Y, Scherer MN, Farkas S, Aslanidis C, Buechler C. Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension. Eur J Clin Invest. 2013;43:926-932. [PMID: 23855493 DOI: 10.1111/eci.12122] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
11 Pampalone M, Corrao S, Amico G, Vitale G, Alduino R, Conaldi PG, Pietrosi G. Human Amnion-Derived Mesenchymal Stromal Cells in Cirrhotic Patients with Refractory Ascites: A Possible Anti-Inflammatory Therapy for Preventing Spontaneous Bacterial Peritonitis. Stem Cell Rev Rep 2021;17:981-98. [PMID: 33389680 DOI: 10.1007/s12015-020-10104-8] [Reference Citation Analysis]
12 Davies T, Wythe S, O'Beirne J, Martin D, Gilbert-Kawai E. Review article: the role of the microcirculation in liver cirrhosis. Aliment Pharmacol Ther 2017;46:825-35. [PMID: 29023881 DOI: 10.1111/apt.14279] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
13 Eisinger K, Krautbauer S, Wiest R, Weiss TS, Buechler C. Reduced serum chemerin in patients with more severe liver cirrhosis. Exp Mol Pathol 2015;98:208-13. [PMID: 25595667 DOI: 10.1016/j.yexmp.2015.01.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
14 Nanashima A, Tobinaga S, Abo T, Sumida Y, Araki M, Hayashi H, Sakamoto I, Kudo T, Takeshita H, Hidaka S, Sawai T, Hatano K, Nagayasu T. Relationship of hepatic functional parameters with changes of functional liver volume using technetium-99m galactosyl serum albumin scintigraphy in patients undergoing preoperative portal vein embolization: a follow-up report. J Surg Res 2010;164:e235-42. [PMID: 20869076 DOI: 10.1016/j.jss.2010.06.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
15 Risør LM, Bendtsen F, Møller S. Immunologic, hemodynamic, and adrenal incompetence in cirrhosis: impact on renal dysfunction. Hepatol Int 2015;9:17-27. [DOI: 10.1007/s12072-014-9581-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
16 Neong SF, Adebayo D, Wong F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. Expert Rev Gastroenterol Hepatol 2019;13:293-305. [PMID: 30791777 DOI: 10.1080/17474124.2018.1555469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
17 Kimer N, Feineis M, Møller S, Bendtsen F. Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature. Scand J Gastroenterol. 2015;50:129-137. [PMID: 25113796 DOI: 10.3109/00365521.2014.948053] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
18 Henriksen JH, Møller S. Cardiac and systemic haemodynamic complications of liver cirrhosis. Scand Cardiovasc J. 2009;43:218-225. [PMID: 19145534 DOI: 10.1080/14017430802691528] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
19 Catalano D, Trovato GM, Martines GF, Pirri C, Trovato FM. Renal function and severity of bright liver. Relationship with insulin resistance, intrarenal resistive index, and glomerular filtration rate. Hepatol Int. 2011;5:822-829. [PMID: 21484130 DOI: 10.1007/s12072-011-9254-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
20 Uojima H, Hidaka H, Nakayama T, Sung JH, Ichita C, Tokoro S, Masuda S, Sasaki A, Koizumi K, Egashira H, Kako M. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study. World J Gastroenterol 2017; 23(45): 8062-8072 [PMID: 29259382 DOI: 10.3748/wjg.v23.i45.8062] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
21 Erly B, Carey WD, Kapoor B, McKinney JM, Tam M, Wang W. Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options. Semin Intervent Radiol. 2015;32:445-454. [PMID: 26622108 DOI: 10.1055/s-0035-1564794] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
22 Al-Hamoudi WK. Cardiovascular changes in cirrhosis: pathogenesis and clinical implications. Saudi J Gastroenterol. 2010;16:145-153. [PMID: 20616408 DOI: 10.4103/1319-3767.65181] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
23 Uojima H, Kinbara T, Hidaka H, Sung JH, Ichida M, Tokoro S, Masuda S, Takizawa S, Sasaki A, Koizumi K, Egashira H, Kako M. Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites: Correlated factors to tolvaptan in liver cirrhosis. Hepatol Res 2017;47:E14-21. [DOI: 10.1111/hepr.12716] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]